Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
FLNA
Strong SellSinkerFilana Therapeutics, Inc. · Healthcare · United States · $58M · Avg Vol: $228K/d
COMPANY DESCRIPTION
Filana Therapeutics, Inc. is a biotechnology firm dedicated to developing novel small-molecule therapeutics for neurodegenerative and metabolic disorders. The company's competitive moat is built upon its proprietary drug discovery platform that targets cellular stress pathways. It operates as an early-stage, research-driven biotechnology player aiming to address significant unmet medical needs.
FINANCIAL SUMMARY (USD)
| Year | 2021 | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | 0 | 0 | 0 | 0 | — | — | — | — | — |
| EPS | — | -1.90 | -2.32 | -0.53 | -1.88 | — | -0.87 | -0.90 | -1.19 | — |
| Shares | — | 41.7M | 42.2M | 48.2M | 48.3M | +15.7% | 48.3M | — | — | — |
| Debt | 0.2M | 0.1M | 0 | — | — | -41.1% | — | — | — | — |
| Equity | — | 227.5M | 137.5M | 145.7M | 74.4M | -31.1% | — | — | — | — |
| Op CF | — | -77.5M | -82.0M | -116.9M | -32.3M | — | -28.7M | — | — | — |
| Inv CF | — | -2.7M | -0.4M | -0.1M | -0.6M | — | — | — | — | — |
| Fin CF | — | 47.8M | 2.6M | 124.5M | -0.2M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of FLNA are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| FLNA | Filana Therapeutics, Inc.(you) | $58M | 4 | Strong Sell |
| CNTX | Context Therapeutics Inc. | $56M | 6 | Strong Sell |
| HRTX | Heron Therapeutics, Inc. | $62M | 7 | Strong Sell |
| ESLA | Estrella Immunopharma, Inc. | $62M | 1 | Strong Sell |
| IBIO | iBio, Inc. | $68M | 3 | Strong Sell |
| 2257.HK | Sirnaomics Ltd. | $55M | 1 | Strong Sell |
| KALA | KALA BIO, Inc. | $63M | 7 | Strong Sell |
| RNTX | Rein Therapeutics Inc. | $66M | 2 | Strong Sell |
| EXOZ | eXoZymes, Inc. | $67M | 2 | Strong Sell |
| ATYR | aTyr Pharma, Inc. | $53M | 7 | Strong Sell |
Peer medians: ROE -30.2% · P/E 27.0x · Gross margin 58.3%